← Back to all trials
Recruiting
NCT07554508
Belzutifan VHL RCC HK Prospective Registry
Conditions: VHL - Von Hippel-Lindau Syndrome
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 100
Sponsor: Chinese University of Hong Kong
Location: Prince of Wales Hospital Shatin
Summary
This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.
Eligibility Criteria
Inclusion Criteria:
* Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and/or genetic diagnosis.
* The patient decided to use Belzutifan for their treatment.
Exclusion Criteria:
* Tumour requiring immediate resection.
* Pregnancy or unwillingness to use contraception if of childbearing potential.
* Uncontrolled comorbidities (e.g., active infection, severe cardiopulmonary disease).
Source: ClinicalTrials.gov (NCT07554508). StuddyBuddy aggregates publicly available trial information.
